ArticleInfection and drug resistance2026
Polymyxin-Associated Neurotoxicity: A Case of Guillain-Barré Syndrome Temporally Linked to Colistin Methanesulfonate and Respiratory Paralysis with Polymyxin B.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyxins are critical for multidrug-resistant Gram-negative infections, yet severe neurotoxicity remains underrecognized, within Guillain-Barré Syndrome (GBS) has not been previously reported in association with polymyxin E. We report two cases illustrating a temporal association between polymyxin therapy and severe neurological manifestations. The first is a case of polymyxin B-induced respiratory paralysis in a patient with bloodstream infection. The second represents the first reported case of GBS associated with polymyxin E (Colistin Methanesulfonate) in a patient with pneumonia; the diagnosis was confirmed electrophysiologically, and the patient responded to immunotherapy. These findings suggest a potential link between polymyxin therapy and severe, atypical neurotoxicity. Clinicians should be vigilant for symptoms ranging from acute paresthesia to GBS, as early recognition and drug discontinuation are crucial to preventing severe outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.